Harpoon Therapeutics Future Growth
Future criteria checks 2/6
Harpoon Therapeutics is forecast to grow earnings and revenue by 10.6% and 35.3% per annum respectively. EPS is expected to grow by 25.7% per annum. Return on equity is forecast to be -220.2% in 3 years.
Key information
10.6%
Earnings growth rate
25.7%
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | 35.3% |
| Future return on equity | -220.2% |
| Analyst coverage | Good |
| Last updated | 11 Mar 2024 |
Recent future growth updates
Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 47 | -76 | -67 | -94 | 5 |
| 12/31/2025 | 23 | -67 | -54 | -64 | 8 |
| 12/31/2024 | 21 | -56 | -33 | -51 | 8 |
| 12/31/2023 | 38 | -26 | -16 | -40 | 8 |
| 9/30/2023 | 37 | -30 | -69 | -69 | N/A |
| 6/30/2023 | 47 | -40 | -77 | -77 | N/A |
| 3/31/2023 | 35 | -59 | -84 | -83 | N/A |
| 12/31/2022 | 32 | -68 | -90 | -89 | N/A |
| 9/30/2022 | 32 | -71 | -88 | -88 | N/A |
| 6/30/2022 | 23 | -76 | -84 | -84 | N/A |
| 3/31/2022 | 21 | -75 | -129 | -129 | N/A |
| 12/31/2021 | 24 | -117 | -122 | -122 | N/A |
| 9/30/2021 | 27 | -107 | -121 | -120 | N/A |
| 6/30/2021 | 26 | -103 | -114 | -113 | N/A |
| 3/31/2021 | 23 | -99 | -10 | -9 | N/A |
| 12/31/2020 | 17 | -50 | -9 | -9 | N/A |
| 9/30/2020 | 12 | -53 | 39 | 40 | N/A |
| 6/30/2020 | 10 | -55 | 40 | 43 | N/A |
| 3/31/2020 | 8 | -55 | -11 | -8 | N/A |
| 12/31/2019 | 6 | -56 | -6 | -3 | N/A |
| 9/30/2019 | 5 | -51 | -46 | -43 | N/A |
| 6/30/2019 | 4 | -42 | -41 | -39 | N/A |
| 3/31/2019 | 4 | -36 | -33 | -32 | N/A |
| 12/31/2018 | 5 | -27 | -28 | -27 | N/A |
| 9/30/2018 | 4 | -23 | -9 | -8 | N/A |
| 12/31/2017 | 1 | -17 | -1 | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HARP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HARP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HARP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HARP's revenue (35.3% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: HARP's revenue (35.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HARP is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/11 14:02 |
| End of Day Share Price | 2024/03/11 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Harpoon Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Arlinda Lee | Canaccord Genuity |
| Jennifer Kim | Cantor Fitzgerald & Co. |